DPM1-CDG means dolichyl-phosphate mannosyltransferase 1 catalytic subunit congenital disorder of glycosylation. It is a very rare inherited metabolic disease. In this condition, the DPM1 gene does not work the right way, so the body cannot make some sugar chains normally. These sugar chains are important because the body uses them to build and finish many proteins. When this sugar-adding process is weak, many organs can be affected, especially the brain, nerves, eyes, muscles, and growth. That is why children with DPM1-CDG can have development delay, low muscle tone, seizures, microcephaly, eye problems, and movement problems. [GARD] [Orphanet] [GeneReviews]
DPM1-CDG means dolichyl-phosphate mannosyltransferase 1 catalytic subunit congenital disorder of glycosylation. It is an ultra-rare inherited metabolic disease caused by harmful changes in the DPM1 gene. This gene helps the body make dolichol-phosphate-mannose, a sugar donor needed for normal glycosylation. When this pathway does not work well, many proteins and lipids are built incorrectly, so the brain, nerves, muscles, eyes, liver, feeding system, and growth can all be affected. Reported features include developmental delay, hypotonia, seizures, microcephaly, eye problems, neuropathy, and gastrointestinal problems, but severity varies widely from child to child.
DPM1-CDG is a very rare inherited metabolic disease. It happens when both copies of the DPM1 gene do not work properly, so the body cannot make enough dolichol-phosphate-mannose, a small but very important sugar donor needed for normal protein and lipid glycosylation. Because glycosylation helps many organs work normally, DPM1-CDG can affect the brain, muscles, feeding, growth, eyes, and overall development. Reported features include developmental delay, low muscle tone, seizures, microcephaly, weakness, and eye problems. At present, there is no proven cure that corrects the basic gene defect, so treatment is mostly supportive and tailored to the person’s symptoms. [GeneReviews] [Orphanet] [Case report]
DPM1-CDG is also called CDG-Ie. “Congenital” means present from birth, “disorder of glycosylation” means the body has trouble attaching sugar chains to proteins and fats, and “DPM1” is the gene involved. When this process fails, cells cannot build or use many important molecules in the normal way. That is why children with DPM1-CDG often have a multisystem illness instead of a problem in only one organ. In published reports, the condition ranges from severe infant disease to milder forms, but it remains an ultra-rare disorder. [GeneReviews] [NIH GARD] [Frontiers]
This disease belongs to the large group called congenital disorders of glycosylation, often shortened to CDG. “Congenital” means present from birth. “Disorder of glycosylation” means the body has trouble attaching sugars to proteins and lipids. These sugars are not just for energy. They help proteins fold correctly, travel to the right place, stay stable, and do their jobs. When glycosylation is defective, the body may show signs in many systems at the same time. DPM1-CDG is one of these multisystem CDG conditions. [NCBI Bookshelf] [MedGen]
Another names
DPM1-CDG is also called congenital disorder of glycosylation type Ie, CDG-Ie, and sometimes DPM1 deficiency. Some databases also describe it as DPM1-related congenital disorder of glycosylation. These names refer to the same disorder. [ClinVar] [GTR] [Orphanet]
Types
DPM1-CDG itself is usually treated as one specific genetic subtype of CDG, not a disease with many formal subtypes. But doctors may describe it in a few practical ways:
1. Classic early-onset DPM1-CDG. This is the more recognized form. Symptoms often begin in infancy with developmental delay, hypotonia, seizures, microcephaly, and eye findings. [GARD] [Orphanet]
2. Severe multisystem form. Some children have broader disease with feeding trouble, gastrointestinal problems, liver-related findings, coagulation changes, neuropathy, and marked neurologic involvement. [Case report] [Liver review]
3. Milder or variable form. A few reported people had a less severe picture with hypotonia, ataxia, and intellectual disability, showing that the disease can vary from person to person. [GeneReviews]
Causes
1. Pathogenic changes in the DPM1 gene. The main cause of DPM1-CDG is a disease-causing variant in the DPM1 gene. This gene gives instructions for making part of the dolichol-phosphate mannose synthase complex. [GTR] [ClinVar]
2. Autosomal recessive inheritance. A child usually gets one altered copy from each parent. Parents are often healthy carriers because one working copy can be enough for them. [GeneReviews]
3. Missense variants. Some patients have a single-letter DNA change that changes one amino acid in the protein. This can weaken the protein instead of removing it completely. [ClinVar] [Case report]
4. Nonsense variants. Some variants create an early stop signal. Then the body makes a shortened protein that usually cannot work well. [ClinVar]
5. Frameshift variants. Small deletions or insertions can shift the reading frame of the gene. This often damages the whole protein message. [ClinVar]
6. Splice-site variants. Some changes affect how the gene message is cut and joined. Then the final protein may be built incorrectly. [ClinVar]
7. Large deletions. In rare cases, a bigger loss in the DPM1 region can remove all or part of the gene. That can stop normal protein production. [ClinVar]
8. Loss of DPM1 enzyme function. Even though the DNA change is the root cause, the disease happens because the altered gene leads to low or abnormal enzyme activity. [GTR] [Original discovery cited in GTR]
9. Low dolichol-phosphate-mannose production. DPM1 helps make dolichol-phosphate-mannose, an important sugar donor used in glycosylation pathways. If this step fails, downstream steps also fail. [NCBI Bookshelf] [GTR]
10. Defective N-linked glycosylation. One major result is poor N-glycosylation, which means some proteins do not receive their normal sugar chains. This is central in many CDG disorders, including DPM1-CDG. [GeneReviews] [Neurology review]
11. Defective O-mannosylation. Dolichol-phosphate-mannose is also used in other glycosylation pathways, including O-mannosylation, so more than one system can be affected. [GARD] [NCBI Bookshelf]
12. Defective GPI-anchor synthesis support. This molecule is also needed in pathways related to GPI-anchor formation, which helps attach some proteins to the cell surface. [NCBI Bookshelf]
13. Abnormal protein folding. When glycosylation is wrong, proteins may not fold into the right shape. Poorly folded proteins often do not work well or are removed by the cell. [NCBI Bookshelf]
14. Abnormal protein stability. Some proteins break down too quickly when their sugar chains are missing or incomplete. This can reduce the amount of working protein in tissues. [MedGen] [NCBI Bookshelf]
15. Brain vulnerability. The brain depends heavily on correctly glycosylated proteins for development and signaling, so neurologic problems are common in DPM1-CDG. [Orphanet] [Neurology review]
16. Eye tissue vulnerability. Eye structures also rely on normal glycosylation, which helps explain retinopathy, nystagmus, and strabismus seen in reported patients. [GARD] [Orphanet]
17. Peripheral nerve involvement. Some patients develop neuropathy because nerve function and myelin-related biology can be disturbed in glycosylation disorders. [Orphanet] [Neurology review]
18. Gastrointestinal involvement. A few reported patients had severe gut problems, including food protein-induced enterocolitis syndrome, showing that the disease can affect digestive function too. [Case report]
19. Liver and coagulation pathway involvement. Glycosylation defects can also disturb liver-made proteins and clotting factors, so some patients show elevated liver enzymes or low antithrombin. [Liver review] [GeneReviews]
20. Family carrier status. The disease appears when two nonworking copies come together in one child, so a family history of carrier status or affected siblings can explain why the disorder occurs in that family. [GeneReviews]
Symptoms
1. Global developmental delay. This means a child is slower than expected in learning, movement, speech, or social development. It is one of the most common features reported in DPM1-CDG. [GARD] [Orphanet]
2. Motor delay. Many children are late to hold the head up, sit, crawl, stand, or walk because the nervous system and muscles are affected. [GARD]
3. Hypotonia. Hypotonia means low muscle tone. The baby may feel floppy, have weak posture, and struggle with feeding or movement. [GeneReviews] [Case report]
4. Seizures. Seizures can begin early in life. They happen because abnormal brain function is common in several CDG disorders, including DPM1-CDG. [GARD] [Orphanet]
5. Microcephaly. Microcephaly means the head is smaller than expected for age and sex. It can reflect reduced brain growth. [GARD] [GeneReviews]
6. Eye problems. Reported eye findings include retinopathy, nystagmus, and strabismus. These may affect vision and eye movement. [GARD] [Orphanet]
7. Ataxia. Ataxia means poor balance and unsteady movement. A child may look shaky or clumsy while sitting, standing, or walking. [Orphanet] [GeneReviews]
8. Peripheral neuropathy. This means the peripheral nerves are affected. It can lead to weakness, reduced reflexes, altered sensation, or gait problems. [Orphanet] [Neurology review]
9. Dysmorphic features. Some children have facial or limb features that doctors describe as dysmorphic. This does not change the child’s value, but it can help point toward a genetic diagnosis. [Orphanet] [Case report]
10. Feeding difficulty. Low tone, poor coordination, and gut involvement may make feeding hard in infancy. Some children do not gain weight well. [GeneReviews] [Case report]
11. Gastrointestinal symptoms. Severe gut symptoms have been reported, including enterocolitis-like illness and feeding intolerance. [Case report]
12. Growth problems. When feeding is difficult and the body is under stress, weight gain and overall growth may be poor. [GARD] [Case report]
13. Frequent infections. Some CDG patients have repeated infections because glycosylation helps immune proteins work normally. This is not universal, but it can happen. [GeneReviews] [MedGen]
14. Weakness and tired movement. Children may appear weak because of hypotonia, neuropathy, and developmental motor impairment together. [Neurology review] [Orphanet]
15. Learning and intellectual disability. Some affected children have mild to severe intellectual disability because brain development is strongly affected by the disorder. [GeneReviews] [Neurology review]
Diagnostic tests
1. General physical examination. The doctor first checks the whole body, growth, alertness, posture, feeding ability, and overall development. This simple step helps the doctor see whether the disease looks multisystem, which is common in CDG disorders. [GeneReviews] [GARD]
2. Head circumference measurement. Measuring the head can show microcephaly. This is important because a small head size is a common clue in DPM1-CDG. [GARD] [GeneReviews]
3. Neurologic examination. The doctor checks tone, reflexes, eye movement, coordination, strength, and seizures history. This helps detect hypotonia, ataxia, neuropathy, and other nervous system problems. [Orphanet] [Neurology review]
4. Eye examination. A full eye exam can look for retinopathy, nystagmus, strabismus, or other visual abnormalities reported in DPM1-CDG. [GARD] [Orphanet]
5. Developmental assessment. This is a structured manual or bedside assessment of milestones such as sitting, speech, hand use, and social response. It helps document motor and cognitive delay clearly. [GARD] [GeneReviews]
6. Tone and gait assessment. This hands-on clinical test looks at muscle tone, balance, and walking pattern. It can show hypotonia and ataxia. [Orphanet] [GeneReviews]
7. Serum transferrin glycoform analysis. This is one of the most important screening tests for many N-glycosylation disorders. Abnormal transferrin isoforms can strongly suggest a CDG. [Neurology review] [Clinical characterization study]
8. Transferrin isoelectric focusing (IEF). IEF is a classic biochemical test used to detect abnormal transferrin patterns in CDG. It is often a first-line laboratory clue. [Neurology review] [GTR condition summary]
9. Apolipoprotein C-III analysis. This test may help evaluate some glycosylation defects, especially when a broader glycosylation workup is needed. [Clinical characterization study] [Neurology review]
10. Molecular genetic testing of DPM1. Targeted sequencing of the DPM1 gene can identify disease-causing variants and confirm the diagnosis. [Orphanet diagnostic test]
11. Gene panel testing for CDG. Many centers use a multigene NGS panel because many CDG disorders look similar at the start. [Orphanet diagnostic test]
12. Whole-exome sequencing. If the diagnosis is unclear, exome sequencing can detect pathogenic variants in DPM1 or other rare disease genes. [Orphanet diagnostic test]
13. Variant interpretation with ClinVar or similar databases. After sequencing, the lab checks whether a variant is already known or likely harmful. This helps decide whether the result truly explains the disease. [ClinVar]
14. Liver function tests. Blood tests such as AST and ALT may be used because some CDG patients, including reported DPM1-CDG cases, show liver involvement. [Liver review]
15. Coagulation studies. Testing clotting-related proteins can be important because some glycosylation disorders have abnormal coagulation factors or low antithrombin. [GeneReviews] [Liver review]
16. Metabolic laboratory workup. Doctors often do wider metabolic blood and urine testing to rule out other inherited metabolic diseases that can look similar. [Case report]
17. Nerve conduction study. This electrodiagnostic test checks how fast and how well peripheral nerves carry signals. It can help if neuropathy is suspected. [Orphanet] [Neurology review]
18. Electromyography (EMG). EMG studies muscle electrical activity and can help when weakness, hypotonia, or neuropathy needs deeper evaluation. [Neurology review]
19. Brain MRI. MRI can look for brain structure changes that may appear in CDG disorders, such as atrophy or delayed myelination, and it helps explain neurologic symptoms. [Neurology review]
20. EEG and targeted imaging when needed. An EEG is often used in children with seizures to study brain electrical activity, and additional imaging such as abdominal ultrasound may be used if liver or gastrointestinal disease is suspected. These tests do not prove DPM1-CDG alone, but they help define how much the body is affected. [GeneReviews] [Liver review] [Case report]
DPM1-CDG is a very rare inherited sugar-processing disorder caused by harmful changes in the DPM1 gene. It mainly affects how the body glycosylates proteins, and this can disturb the brain, nerves, eyes, muscles, liver, gut, and development. The most helpful clues are usually developmental delay, hypotonia, seizures, microcephaly, and eye problems, and the most important confirming tests are transferrin glycoform studies and genetic testing of DPM1. Because this is a rare disease with variable severity, diagnosis is best made by a metabolic, genetic, and neurologic team. [GARD] [Orphanet] [GeneReviews]
Non-pharmacological treatments
1) Metabolic specialist follow-up. Regular follow-up with a clinician experienced in CDG helps organize testing, nutrition, seizure care, clotting checks, and growth monitoring. The purpose is early detection of complications. The mechanism is simple: frequent review allows problems to be found before they become emergencies.
2) Physical therapy. Many children with DPM1-CDG have low muscle tone and delayed motor development. Physical therapy aims to improve posture, joint range, head control, transfers, balance, and safe mobility. It works by repeated guided movement, strengthening, and motor learning.
3) Occupational therapy. Occupational therapy supports hand use, play skills, seating, daily activities, adaptive devices, and sensory regulation. Its purpose is function and independence. It helps by breaking hard tasks into smaller practiced movements and by modifying the environment.
4) Speech and feeding therapy. If swallowing, oral control, or speech is delayed, speech-language therapy is important. The purpose is safer feeding and better communication. The mechanism is oral-motor training, texture adaptation, positioning, and communication support.
5) Early intervention and developmental programs. Early therapy services can improve function during the most important years of brain development. The purpose is to reduce secondary disability. It works through structured developmental stimulation and family coaching.
6) Individual nutrition planning. Many CDG patients need careful calorie, protein, fluid, and micronutrient planning because feeding can be poor and growth may falter. The purpose is better growth and energy. The mechanism is matching intake to needs and tolerance.
7) Texture-modified feeding. Thickened liquids, purees, or soft foods may reduce choking and improve oral intake in children with weak swallowing or poor coordination. The purpose is safer swallowing. The mechanism is slowing bolus flow and making swallowing easier to control.
8) High-calorie feeding strategies. Small frequent meals, fortified foods, and calorie-dense formulas are often used when feeding time is long or intake is poor. The purpose is preventing failure to thrive. The mechanism is delivering more energy in a smaller volume.
9) Feeding tube support when needed. Some CDG patients with severe feeding problems benefit from nasogastric or gastrostomy feeding. The purpose is reliable nutrition and medicine delivery. The mechanism is bypassing unsafe or inefficient oral feeding.
10) Seizure safety planning. Families need a seizure action plan, rescue medicine instructions, supervision during bathing, and emergency guidance. The purpose is injury prevention and faster treatment. The mechanism is preparedness and early response.
11) Vision assessment and low-vision support. Eye problems such as nystagmus, retinopathy, or strabismus may occur. The purpose is protecting visual development and function. It helps by detecting treatable problems early and adding vision support tools when needed.
12) Hearing and communication assessment. Even when hearing seems normal, developmental disorders benefit from formal review. The purpose is avoiding missed communication barriers. The mechanism is identifying deficits early and matching therapy or devices to need.
13) Orthopedic positioning and seating. Supportive seating, braces, standing devices, and contracture prevention can help children with hypotonia or poor trunk control. The purpose is comfort, alignment, and better function. The mechanism is mechanical support plus better posture for breathing and feeding.
14) Sleep routine support. Neurologic disease and seizures can disturb sleep. Good sleep hygiene, positioning, and management of reflux or pain may help. The purpose is better rest and daytime function. The mechanism is reducing triggers that fragment sleep.
15) Gastrointestinal support. Constipation, reflux, vomiting, or feeding intolerance may worsen nutrition. Non-drug care includes meal pacing, positioning after feeds, hydration, and formula changes directed by clinicians. The purpose is better tolerance. The mechanism is lowering stress on the gut.
16) Infection prevention basics. Vaccination, good hand hygiene, avoiding sick contacts when possible, and quick medical review during fever are important in medically fragile children. The purpose is lowering infection risk. The mechanism is reducing exposure and enabling early treatment.
17) Regular liver and clotting monitoring. Some CDG patients can have abnormal liver enzymes or coagulation problems. The purpose is preventing bleeding or missed organ involvement. The mechanism is surveillance with labs and careful planning before invasive procedures.
18) Genetic counseling. DPM1-CDG is inherited in an autosomal recessive pattern. The purpose is helping families understand recurrence risk and future pregnancy options. The mechanism is education and informed decision-making.
19) Palliative and supportive care for severe disease. In very severe cases, supportive care also includes pain relief, comfort-focused feeding decisions, and family support. The purpose is quality of life. The mechanism is symptom relief and goal-based care.
20) Family training and psychosocial support. Parents often manage seizures, feeding, transport, therapy, and specialist visits. Teaching and emotional support improve home care. The purpose is better long-term care. The mechanism is caregiver confidence and reduced burnout.
Drugs treatment:
For DPM1-CDG, I need to be precise: there are no FDA-approved drugs that specifically cure DPM1-CDG itself. Medicines are used to treat symptoms or complications, especially seizures, reflux, spasticity, constipation, thyroid problems, and acute bleeding or nutritional problems when present. That is the most evidence-based way to discuss drugs for this condition.
Levetiracetam is commonly used for seizures. It is an antiseizure medicine approved for certain seizure types, and clinicians may choose it in children with CDG when seizures are part of the picture. Dosing is individualized by age, weight, kidney function, and seizure type. The purpose is seizure reduction. The mechanism involves modulation of synaptic vesicle protein SV2A, which helps calm abnormal electrical firing. Side effects can include sleepiness, irritability, weakness, and behavioral changes.
Topiramate is another antiseizure option when seizures are difficult to control. It is FDA-approved for epilepsy indications, including pediatric use in selected settings. The purpose is seizure control. It works through several actions, including effects on sodium channels, GABA pathways, and glutamate signaling. Side effects can include sleepiness, poor appetite, metabolic acidosis, kidney stones, and slowed growth or cognition in some patients.
Diazepam rectal gel may be used as a rescue medicine for prolonged seizure clusters at home when prescribed by a neurologist. The purpose is to stop an emergency seizure episode quickly. It works by enhancing GABA activity in the brain. Important side effects include sleepiness, breathing depression, and poor coordination, so it must be used exactly as instructed.
Baclofen may help when stiffness or painful muscle spasms become a problem in children with neurologic impairment. The purpose is reducing spasticity and improving comfort or positioning. It works mainly through GABA-B receptor activity in the spinal cord. Side effects can include drowsiness, weakness, dizziness, low muscle tone, and withdrawal problems if stopped suddenly.
Omeprazole can be used when reflux is contributing to feeding pain, vomiting, or poor intake. The purpose is reducing stomach acid. The mechanism is proton pump inhibition in stomach parietal cells. Side effects can include diarrhea, headache, and with long-term use, possible mineral or infection-related concerns.
Levothyroxine is only used if thyroid testing shows hypothyroidism. The purpose is hormone replacement. It works by providing T4, which tissues convert to active thyroid hormone. Side effects of excess dosing include fast heartbeat, sweating, irritability, and weight loss. It should not be used unless there is a real thyroid indication.
Other medicines may be chosen case by case for constipation, nutrition, clotting support, infection treatment, or ICU care, but the exact drug depends on the child’s symptoms and lab results. For DPM1-CDG, medicine choice should be symptom-led, specialist-led, and individualized rather than copied from a general list.
Dietary molecular supplements
There is no proven supplement that corrects DPM1-CDG itself, but supplements may sometimes be used to support general nutrition when blood tests or diet review show a need. Common examples are vitamin D, calcium, iron, folate, vitamin B12, zinc, selenium, omega-3 fatty acids, multivitamins, and protein supplements. Their purpose is to correct deficiency and support growth, bone health, blood production, or general nutrition. Their mechanism is replacement of missing nutrients rather than repair of the glycosylation defect. They should be used only after clinician review because unnecessary supplements can also cause harm.
Immunity booster, regenerative, and stem-cell drugs
I cannot honestly provide 6 evidence-based immunity-booster, regenerative, or stem-cell drugs for DPM1-CDG, because no such treatments are currently established or FDA-approved for this disease. Reviews of CDG therapy describe exciting research directions, but for DPM1-CDG these approaches are still not standard proven care. The evidence-based answer is that treatment remains supportive at this time.
Surgeries or procedures
1) Gastrostomy tube placement may be done when oral feeding is unsafe or not enough for growth. 2) Nasogastric tube placement is a temporary procedure for short-term nutrition or medicines. 3) Strabismus surgery may be considered in selected children with important eye misalignment. 4) Orthopedic procedures may be needed if deformity or contracture becomes severe. 5) Pleural-pericardial window or related drainage procedures are described in some CDG settings for recurrent fluid complications, though not specific to every DPM1-CDG case. These procedures do not cure the gene problem; they treat a complication to improve safety or daily function.
Prevention points
Because DPM1-CDG is genetic, it usually cannot be prevented after conception, but complications can be reduced. Helpful steps are: early diagnosis, regular neurology review, nutrition review, swallowing checks, vaccination, infection precautions, seizure rescue planning, eye follow-up, clotting/liver monitoring, and genetic counseling before future pregnancies. These steps help prevent avoidable injury, malnutrition, delayed care, or missed complications.
When to see doctors urgently
Seek urgent medical care for new or longer seizures, repeated vomiting, dehydration, trouble breathing, blue lips, choking, marked sleepiness, sudden weakness, fever in a fragile child, poor feeding, bleeding, black stool, severe constipation, or a sudden drop in alertness. Routine follow-up is also important for slowed development, vision concerns, poor growth, or repeated infections. In ultra-rare neurologic CDG disorders, early review matters because children can worsen quickly.
What to eat and what to avoid
In general, choose foods or formulas that are safe to swallow, calorie-dense when growth is poor, protein-adequate, and easy to digest. Good choices may include clinician-approved formula, yogurt if tolerated, eggs, soft fish, mashed vegetables, nut butters if safe, oats, rice, lentils, and fortified foods. Avoid foods that clearly trigger choking, reflux, vomiting, or allergy symptoms; avoid very hard textures if swallowing is weak; and avoid unplanned restrictive diets unless a specialist recommends them. There is no universal DPM1-CDG curative diet, so feeding should be personalized.
FAQs
What is DPM1-CDG? It is a rare inherited glycosylation disorder caused by DPM1 gene changes.
Is it curable? No proven cure yet.
Is treatment supportive? Yes, mainly supportive.
Can it cause seizures? Yes, often.
Can it affect feeding? Yes.
Can it affect eyes? Yes.
Can it affect development? Yes.
Is it inherited? Usually autosomal recessive.
Should siblings be tested? Often yes after genetics review.
Is there a special diet cure? No proven one.
Do all children look the same clinically? No, severity varies.
Are stem cells proven? No.
Can adults have it? Rarely, and severity varies.
Does therapy help? It can improve function and comfort.
Why is multidisciplinary care important? Because many organs can be involved at the same time.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: April 01, 2025.
